August 4, 2025- BD announced it has submitted an application to the U.S. Food and Drug Administration for a new, at-home human papillomavirus (HPV) test that enables patients to self-collect a sample in the comfort of their own home using a swab the size of a Q-tip that simplifies processing at the lab and reports more high-risk strains of HPV than any other test on the market today.
When available, the new HPV test from BD will include a state-of-the-art self-collection swab technology that offers a safe, simple and non-invasive collection experience without the need for liquids or complex devices. The stability of the swab also allows for convenient mailing from home to the lab, removing logistical barriers and supporting broader participation in cervical cancer screening programs.
At the lab, the self-collected swab needs no manual sample preparation by clinical laboratory technologists, which allows them to focus on higher value work. The sample is simply placed into the BD COR™ System and the fully automated process uses sophisticated robotics to prepare, analyze and report results for each sample. Using an internal cellular control and minimizing manual touch and intervention ensures the integrity of the specimen from collection to delivery of dependable, high-quality results.